- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Norcross Today
By the People, for the People
Galectin Therapeutics Beats Q1 Earnings Expectations
The biotech firm exceeded analyst forecasts by $0.02 per share in its latest quarterly report.
Mar. 31, 2026 at 12:20pm
Got story updates? Submit your updates here. ›
Galectin Therapeutics' strong quarterly earnings report highlights the robust financial machinery powering the biotech firm's drug development efforts.Norcross TodayGalectin Therapeutics (NASDAQ:GALT), a clinical-stage biotech company focused on developing novel therapies for fibrotic, inflammatory and malignant diseases, reported its first quarter financial results on Tuesday. The company posted a loss of $0.08 per share, beating the consensus analyst estimate of a $0.10 per share loss.
Why it matters
Galectin's strong Q1 earnings performance may signal progress in the development of its lead drug candidate, belapectin, which is currently in Phase 2 clinical trials for the treatment of non-alcoholic steatohepatitis (NASH) with cirrhosis. Positive results could boost investor confidence and the company's stock price.
The details
Galectin Therapeutics reported a loss of $0.08 per share for the first quarter, exceeding the average analyst estimate of a $0.10 per share loss. The company's stock opened at $2.57 on Tuesday, down from a 52-week high of $7.13. Galectin is developing belapectin, a galectin-3 inhibitor, as a potential treatment for NASH with cirrhosis, a serious liver disease.
- Galectin Therapeutics reported its Q1 2026 earnings results on Tuesday, March 31, 2026.
- The company's stock opened at $2.57 on the day of the earnings release.
The players
Galectin Therapeutics
A clinical-stage biotechnology company focused on developing novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases.
Joel Lewis
The CEO of Galectin Therapeutics.
Jack W. Callicutt
The CFO of Galectin Therapeutics.
What’s next
Galectin Therapeutics will continue to advance its lead drug candidate, belapectin, through Phase 2 clinical trials for the treatment of NASH with cirrhosis. Positive results from these trials could lead to further development and potential regulatory approval.
The takeaway
Galectin Therapeutics' strong Q1 earnings performance, with a narrower-than-expected loss, suggests progress in the development of its lead drug candidate for a serious liver disease. This could boost investor confidence and the company's stock price if the positive momentum continues.
